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D I L E M M A S  IN BREAST DISEASE 
This section of the journal addresses special aspects of breast dis- 
ease management that presents a challenge to practicing clinicians, 
generally for which there is no clear answer or consensus. Invited 
consultants who are authorities in the field summarize available 
data in order to clarify the issue and facilitate rational decisions. 
Is Breast Irradiation Routinely 
Necessary Following Conservation 
Therapy of Breast Cancer? 
INTRODUCTION The gradual acceptance of Fisher’s “Alternative Hypothesis” of the 
biology of breast cancer, as confirmed by numerous prospective trials of the past twenty 
years, has served to support the validity of breast conservation therapy, Appropriate 
questions are being raised as to whether irradiation is always necessary, especially in 
view of current evidence that local recurrence of breast cancer does not appear to 
adversely affect survival rates. We need to investigate the costslbenefit of accepting a 
higher rate of local breast cancer occurrence in order to avoid the expense, morbidity, 
and inconvenience of adjuvant radiation therapy following conservation surgery. Is there 
a subset of women with a specific group of tumors in whom the omission of radiation 
would be acceptable? There is no clear answer at present, but the following essays by 
Drs. Pierce, Lichter, and Nemoto strive to summarize the available data and add clarity 
to the issue. 
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reatment policies that direct our management deci- maintenance of local (breast) control following breast- T sions are often based upon clinical observations in the preserving surgery is clearly, however, an exception to this 
absence of data. The importance of radiotherapy in the rule. Every randomized trial to date comparing limited 
breast surgery with or without breast radiotherapy has 
shown a highly statistically significant reduction of in- 
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breast failures -by the addition of radiotherapy for both 
invasive and non-invasive (intraductal) disease (1-6). 
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Therefore, deviation from this standard of care can only 
be considered when omission of breast radiotherapy is not 
expected to significantly affect patient outcome. Can we 
select patients with clinical factors that predict for such 
a low risk for breast recurrence following limited surgery 
that omitting breast radiotherapy represents no hazard to 
them? 
It is first important to emphasize the magnitude of ben- 
efit with respect to local control when radiotherapy is ad- 
ministered following conservative surgery. Four trials have 
randomized women with invasive disease following local 
excision to observation versus breast radiotherapy only. 
In the Milan trial, women with small breast cancers (less 
than 2.5 cm in diameter) were randomized following quad- 
rantectomy to radiotherapy (RT) or no  additional therapy 
(1). With a median follow-up of only 39 months, 8.8% 
of women who did not undergo radiotherapy experienced 
a local recurrence compared to only 0.3% of thoese who 
had radiotherapy. In a similar trial sponsored by the 
Uppsala-Orebro Breast Cancer Group, lesions 2 cm or less 
treated with excisional biopsy and negative margins were 
followed with and without RT (2). Recurrence rates were 
2.3”/0 with RT versus 18.4% without RT with 63 month 
median follow-up. A third study was reported by the On- 
tario Cancer Institute and Princess Margaret Hospital ( 3 ) .  
Node-negative women with tumors 4 cm or less ran- 
domized to receive RT experienced a 5.5’10 local breast 
failure rate compared to 25.7% in the control group at 
43 months median follow-up. The National Surgical Ad- 
juvant Breast and Bowel Project (NSABP) B-06 study 
reported a cumulative incidence of breast recurrence of 
12% with RT versus 53% without RT at 10 years (4). 
Thus, despite variation in selection criteria, radiotherapy 
has been needed to consistently reduce breast failure. 
These trials are of additional benefit in highlighting clin- 
ical and pathologic factors that might predict for a favora- 
ble outcome with conservative surgery only. Factors that 
appear to predict for decreased risk of breast failure in the 
absence of radiotherapy include a wide surgical resection 
with attention to margins such as quadrantectomy, tumor 
size less than or equal to 2 cm, unifocal disease, the ab- 
sence of an extensive intraductal component (EIC), and 
increasing age. 
Using these and other restrictive criteria, studies have 
examined the outcome of conservative surgery only in 
highly selected populations. At, the University of Miami, 
patients with primary tumors less than or equal to 2.5 cm, 
clear resection margins, no vascular, lymphatic, or peri- 
neural invasion, and minimal to no in situ disease are 
offered breast-conserving therapy with and without RT 
(7). With 80 month median follow-up, the five year local 
recurrence rate was 6% for surgery only and 0% for pa- 
tients choosing to receive radiotherapy. The Cleveland 
Clinic published their retrospective experience with par- 
tial mastectomy with or without radiotherapy for patients 
with stage 0, I ,  or I1 disease (8) .  With a mean follow-up 
of 8.5 years, there was a significant increase in local recur- 
rence in the absence of RT at eight years after surgery. Lo- 
cal control rates at 12 years of follow-up were reportedly 
similar, however, for women treated with or without ra- 
diotherapy. When breast recurrence rates were compared 
by stage, radiotherapy did not appear to significantly ben- 
efit women with stage 0 or I disease. However, in-breast 
failure was significantly reduced using adjuvant radiother- 
apy in patients with stage I1 disease, with five and ten year 
reported local recurrence rates of 4 and 10 percent with 
RT versus 11 and 22 percent without RT, respectively. In 
a study at the Joint Center for Radiation Therapy in Bos- 
ton of a group of node-negative women with infiltrating 
ductal carcinoma no greater than 2 cm in size, no evidence 
of lymphatic vessel invasion or EIC, and clear margins of 
at least 1 cm, omission of RT resulted in a three year crude 
local recurrence rate of 7.3% ( 9 ) .  This compares to a 2% 
rate of recurrence at three years using radiotherapy for 
women with less favorable criteria (margin uncertainty, 
younger age, and larger tumors). Analysis of these results 
led to the premature closure of this trial. The authors con- 
cluded that even in a highly selected group of breast can- 
cer patients, there is a substantial risk of early local recur- 
rence for those treated with wide excision alone. Therefore, 
even with highly favorable characteristics, in-breast recur- 
rence rates appear to be greater in the absence of ra- 
diotherapy. 
Alternative strategies to observation and standard ra- 
diotherapy include the use of tamoxifen following limited 
breast surgery. A Scottish Adjuvant Breast Cancer Trial 
demonstrated a 7% rate of breast recurrence for estrogen 
receptor positive tumors treated with tamoxifen in the ab- 
sence of radiotherapy compared to 0% failures with radi- 
otherapy and Tamoxifen (10). Further local therapy fol- 
lowing recurrence (mastectomy or local excision with or 
without radiotherapy) among patients not randomized to 
receive RT has reportedly resulted in comparable rates of 
ultimate local control as patients randomized to RT. Based 
upon this and other series suggesting a local benefit with 
the use of tamoxifen, a NSABP trial is currently randomiz- 
ing patients with tumors less than or equal to 1 cm to RT, 
tamoxifen only, or RT and tamoxifen. 
Although local control is the obvious endpoint when 
considering surgery in the absence of RT, thought must 
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also be given to the possible more subtle effects of increased 
breast failure upon survival. To suggest distant dissemi- 
nation is affected by local recurrence implies Halstedian 
thinking, where en bloc therapy was deemed necessary for 
cure. Although women with earlier stages of disease were 
cured by ablative surgery, the propensity for distant fail- 
ure in the majority of women with breast cancer engen- 
dered an alternative hypothesis, proposed by Fisher, which 
suggested that breast cancer is a systemic disease at incep- 
tion with little, if any, local influence upon survival. NSABP 
trials have shown that while limited surgical procedures 
result in significantly higher rates of breast failure, this has 
not resulted in significantly higher rates of distant dissemi- 
nation (4-6). Conversely, durability of local control has 
not translated into improved survival. Although these con- 
clusions are statistically sound, clinical observations ques- 
tion the comprehensiveness of this hypothesis. It is unques- 
tionable that poorly controlled local disease can provide 
a nidus for tumor dissemination once a critical size is 
reached. The risk for development of metastatic disease 
increases with tumor size, therefore undoubtedly the risk 
must also increase with time in patients with inadequately 
controlled local disease. This rationale argues strongly 
against local therapy having no impact upon survival. Since 
breast cancer represents a heterogeneous disease, it is rea- 
sonable that no one hypothesis is appropriate in every case 
or that the explanations proposed by Halsted and Fisher 
are mutually exclusive. As suggested by Hellman, a third 
hypothesis can be proposed in which development of 
metastases are a function of tumor growth and progres- 
sion (11). Therefore, persistent local disease could in fact 
give rise to metastatic disease. 
The argument for a causal relationship between local 
control and survival is most compelling for patients with 
pure intraductal disease, Data from a randomized trial of 
patients with ductal carcinoma in situ (DCIS) are avail- 
able from the NSABP B-06 study (6).  Although the trial 
was intended for women with invasive stage I or I1 dis- 
ease, 76 cases were retrieved of pure DCIS only. With a 
median follow-up of 83 months, 43% of patients treated 
with lumpectomy only have experienced a breast failure 
compared to only 7% treated with lumpectomy and RT. 
Of the nine patients failing after lumpectomy only, two 
patients with an invasive recurrence have died of disease. 
By comparison, there have been no deaths secondary to 
recurrent disease among patients treated with RT. Al- 
though these results are not significantly different, the ap- 
proximate 50% risk of an invasive recurrence following 
treatment failure in DCIS suggests the potential for de- 
creased survival with inadequate local control. A subse- 
quent NSABP trial for DCIS (B-17) demonstrated a sig- 
nificant event-free survival advantage for patients receiving 
breast radiotherapy due to reduction of ipsilateral breast 
cancers, most notably invasive cancers ( 5 ) .  No survival 
difference was found, but longer follow-up is needed. 
The importance of maximal local control is also evi- 
dent in node-positive stage I1 disease. In every trial ran- 
domizing women to post-mastectomy radiotherapy, a 
reduction in chest wall and/or regional failure has been 
demonstrated. Only recently has this translated into im- 
provement in survival. With maturation of data from the 
Stockholm trial, a significant reduction in distant me- 
tastases and deaths due to breast cancer is seen for pa- 
tients receiving post-mastectomy RT (12). Results of a re- 
cent meta-analysis of post-mastectomy trials also 
demonstrate a trend toward improved survival for patients 
receiving radiotherapy (13). Studies of women treated with 
mastectomy and chemotherapy and randomized to receive 
radiotherapy have also shown a significant benefit in 
disease-free (14, 15) and overall survival (14). Realization 
of a similar benefit in women with early stage disease will 
require significantly larger cohorts of women and long- 
term evaluation. 
In summary, there have yet to be subgroups of women 
identified with invasive or non-invasive disease for whom 
breast-conserving surgery without irradiation has lead to 
comparable local control and survival as with adjuvant 
radiotherapy. Additional clinical trials with well-defined 
criteria randomizing women to radiotherapy or observa- 
tion are needed to identify low-risk patients whose increase 
in breast failure without irradiation is considered accept- 
able, As in prior studies comparing radical mastectomy 
to modified radical mastectomy (MRM), and MRM to 
lumpectomy and radiotherapy, establishing a new standard 
of care can only be achieved through a stepwise methodi- 
cal approach. Since recurrent disease and loss of a breast 
often result in severe psychological distress to a woman, 
it will be important to study local failure as well as suc- 
cess of salvage therapy among patients randomized to ob- 
servation to determine ultimate control while preserving 
the breast. 
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